Tamoxifen

most data

Also seen as: Nolvadex

The Dose Guy’s verdict

Sep 1, 2026
3 sources

The most proven SERM in the toolkit. Tamoxifen has decades of clinical use, breast cancer prevention data that nobody else touches, and a track record in PCT that makes it the default for a reason. It restarts your axis, it catches early gyno, and it does both reliably. Enclomiphene is the modern smart pick with a cleaner side profile, but tamoxifen is the one with 30 years of receipts behind it. The catches are real but manageable: hot flashes, a small clotting risk on long runs, and CYP2D6 genetics that may affect how well you metabolize it. For PCT, pair it with on-cycle hCG and you have the backbone of most restart protocols.

Would I take it?Yes, the proven PCT staple.

What it is

Tamoxifen is a SERM, a selective estrogen receptor modulator, that blocks estrogen in some tissues and mimics it in others. At the breast it is an antagonist, which is why it prevents and reverses gynecomastia. At the hypothalamus it blocks estrogen’s negative feedback, which drives LH and FSH up and restarts testosterone production. At bone it acts as a mild estrogen agonist, which is actually protective. That tissue selectivity is the design: you get the anti-estrogen effect where you want it without wiping estrogen’s benefits everywhere else.

The metabolism matters. Your body converts tamoxifen into endoxifen, its most potent active metabolite, through the CYP2D6 enzyme. If your CYP2D6 is slow, genetically or because another drug is blocking it, you make less endoxifen. About 7 to 10% of people are poor metabolizers. Whether lower endoxifen levels actually translate to worse outcomes is still contested: the largest prospective study, CYPTAM with 667 patients, found no association between endoxifen concentration or CYP2D6 genotype and relapse-free survival. The pharmacology is clear, the clinical consequence is not.

What the research shows

Tamoxifen has the deepest evidence base on this shelf. The breast cancer data alone spans tens of thousands of patients and decades of follow-up:

Five years of adjuvant tamoxifen cut ER-positive breast cancer recurrence nearly in half in the first five years, rate ratio 0.53, and reduced breast cancer mortality by about one third through the first 15 years.Lancet 2011 · patient-level meta-analysis · n=21457

Tamoxifen reduced bicalutamide-induced gynecomastia risk by 82%, risk ratio 0.18. The same reduction held for breast pain.J Endocrinol Invest 2025 · meta-analysis · 9 RCTs

After median 9.7-year follow-up, TAM-01 recorded 25 breast cancers with tamoxifen 5 mg daily for three years versus 41 with placebo, hazard ratio 0.58. Number needed to treat: 14.JCO 2023 · TAM-01 RCT · n=500 · 10yr follow-up

No PCT-specific randomized trial exists. The axis-restart use is extrapolated from hypogonadism and fertility data, combined with decades of clinical familiarity.as of Aug 2026

Realistic protocols

Tamoxifen is the anchor of the standard PCT protocol, and for good reason: it reliably drives LH and FSH back up, it protects against gyno while estrogen rebounds, and you can dose it simply. The usual PCT run is 20 mg per day for four to six weeks, starting after your last compound has cleared, roughly two weeks after a long-ester injectable or immediately after orals. Some older protocols front-load at 40 mg for the first week, but there is no strong reason to: 20 mg saturates the receptor, and the higher dose just brings more hot flashes.

If you ran hCG on cycle, your testes are already primed and recovery is faster. If you did not, consider a short hCG bridge, 1000 to 1500 IU every other day for 10 days, before starting tamoxifen. Tamoxifen tells your brain to send the restart signal, but if your testes spent months offline and atrophied, they need hCG to wake up before the signal means anything.

For gyno prevention on cycle, 10 to 20 mg daily catches most early signs. If you already have a lump, tamoxifen can reverse early-stage gyno, but raloxifene outperforms it for established tissue.

Two drug interactions to know. SSRIs like paroxetine and fluoxetine block CYP2D6 and cut your endoxifen levels, making tamoxifen less effective. If you are on one, either switch the antidepressant or switch the SERM. Grapefruit juice hits CYP3A4, the other enzyme in the pathway, and is worth avoiding while you are on tamoxifen.

PCT20 mg/dayFour to six weeks. Start after your last compound clears.

With hCG bridge20 mg/dayStart tamoxifen after a 10-day hCG priming block.

On-cycle gyno10–20 mg/dayCatches early signs. If a lump is forming, consider raloxifene.

Side effects

Well characterized from decades of use. Most are dose-dependent and tolerable at the doses people actually run:

commonHot flashes. The most reported side at any dose. Annoying, not dangerous, and a sign the SERM is working.

commonMood changes, emotional flatness, or reduced libido during PCT. Some of this is the recovery itself, not just the drug.

monitorLong-term use raises venous thromboembolism risk. At PCT durations of four to six weeks the risk is minimal, but it is real on extended runs.

monitorCYP2D6 poor metabolizers produce less endoxifen. Whether that changes clinical outcomes is unresolved, but if tamoxifen feels like it is doing nothing, get your CYP2D6 genotyped or switch to enclomiphene, which does not depend on the same pathway.